Inhibition of RAS-driven signaling and tumorigenesis with a pan-RAS monobody targeting the Switch I/II pocket
Sign Up to like & getrecommendations! Published in 2022 at "Proceedings of the National Academy of Sciences of the United States of America"
DOI: 10.1073/pnas.2204481119
Abstract: Significance RAS is mutated in nearly 20% of human cancers and has few direct, efficacious inhibitors. Here, we developed a synthetic protein, JAM20, to discover potential regions on RAS that may be used for inhibition.… read more here.
Keywords: switch; switch pocket; targeting switch; inhibition ras ... See more keywords
THER-07. INHIBITION OF THE RAS SIGNALING ENHANCES VIRAL ONCOLYSIS IN MALIGNANT GLIOMAS
Sign Up to like & getrecommendations! Published in 2020 at "Neuro-Oncology"
DOI: 10.1093/neuonc/noaa222.857
Abstract: Abstract Pediatric malignant glioma indicates rapid proliferation, widely infiltrative properties and resistance to various therapies, and carries a very poor prognosis. There are methods of using virus within novel therapies under development against malignant neoplasms,… read more here.
Keywords: inhibition ras; vaccinia virus; ras signaling; stage ... See more keywords
Abstract B023: Inhibition of RAS signaling and tumorigenesis through targeting novel vulnerabilities
Sign Up to like & getrecommendations! Published in 2023 at "Molecular Cancer Research"
DOI: 10.1158/1557-3125.ras23-b023
Abstract: RAS GTPases are important mediators of oncogenesis with nearly 30% of human tumors harboring mutant RAS proteins. However, pharmacological inhibition of RAS has proven challenging. We have employed Monobody technology to discover novel vulnerabilities in… read more here.
Keywords: signaling tumorigenesis; novel vulnerabilities; ras signaling; inhibition ras ... See more keywords